Hengji Medicine

Hengji Medicine is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative cancer immunotherapies. The company specializes in creating next-generation biologics, particularly bifunctional fusion proteins designed to target multiple immune-suppressive pathways simultaneously. Its lead candidate, HJ001, is a PD-L1/TGF-beta bifunctional fusion protein currently undergoing Phase 2 clinical trials for advanced solid tumors. Hengji Medicine's pipeline also includes monoclonal antibodies and small molecule candidates targeting HER2 and PD-1, among other oncogenic targets. By leveraging its proprietary R&D platforms, the company aims to provide more effective and durable treatment options for patients with refractory cancers.